Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Urologic Oncology in Focus: Insights, Trends, Evidence-Based Practices and Future...
share announcement

Urologic Oncology in Focus: Insights, Trends, Evidence-Based Practices and Future Directions

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 5681

Special Issue Editor

Prof. Dr. Bhaskar K. Somani

E-Mail Website
Guest Editor
University Hospital Southampton NHS Trust, University of Southampton, Southampton, UK
Interests: endourology; urinary tract infections; benign prostate disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, titled "Urologic Oncology in Focus: Insights, Trends, Evidence-Based Practices, and Future Directions", offers a comprehensive overview of the current state of the art in urologic oncology. It brings together expert contributions that highlight key insights, emerging trends, evidence-based practices, and potential future directions in the field. This Special Issue covers various urologic cancers such as prostate, bladder, kidney, and testicular cancer, along with rare urologic malignancies. Topics discussed include diagnostic techniques, treatment modalities, surgical interventions, targeted therapies, immunotherapy, precision medicine, and supportive care. This Special Issue is an invaluable resource for healthcare professionals, researchers, and policymakers involved in urologic oncology, offering up-to-date insights to improve patient care and outcomes.

Prof. Dr. Bhaskar K. Somani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urologic oncology
  • prostate cancer
  • bladder cancer
  • kidney cancer
  • testicular cancer
  • targeted therapies
  • immunotherapy
  • precision medicine
  • supportive care
  • rare urological cancers
  • imaging for urological cancers

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

9 pages, 269 KiB  
Article
No Association of Trichomonas vaginalis Seropositivity with Advanced Prostate Cancer Risk in the Multiethnic Cohort: A Nested Case-Control Study
by Michelle Nagata, Anne Tome, Kami White, Lynne R. Wilkens, Song-Yi Park, Loïc Le Marchand, Christopher Haiman and Brenda Y. Hernandez
Cancers 2023, 15(21), 5194; https://doi.org/10.3390/cancers15215194 - 28 Oct 2023
Cited by 1 | Viewed by 1014
Abstract
The potential involvement of a sexually transmitted agent has been suggested to contribute to the high number of prostate cancers in the United States and worldwide. We investigated the relationship of Trichomonas vaginalis seropositivity with prostate cancer risk in a nested case–control study [...] Read more.
The potential involvement of a sexually transmitted agent has been suggested to contribute to the high number of prostate cancers in the United States and worldwide. We investigated the relationship of Trichomonas vaginalis seropositivity with prostate cancer risk in a nested case–control study within the Multiethnic Cohort in Hawaii and California using blood samples collected prior to cancer diagnoses. Incident cases of advanced prostate cancer (intermediate- to high-grade based on Gleason score ≥ 7 and/or disease spread outside the prostate) were matched to controls by age, ethnicity, and the date of blood collection. T. vaginalis serostatus was measured using an ELISA detecting IgG antibodies against a recombinant T. vaginalis α-actinin protein. Seropositivity to T. vaginalis was observed in 35 of 470 (7.4%) cases and 26 of 470 (5.5%) controls (unadjusted OR = 1.47, 95% CI 0.82–2.64; adjusted OR = 1.31, 95% CI 0.67–2.53). The association was similarly not significant when cases were confined to extraprostatic tumors having regional or distant spread (n = 121) regardless of grade (unadjusted OR = 1.37, 95% CI 0.63–3.01; adjusted OR = 1.20, 95% CI 0.46–3.11). The association of T. vaginalis with prostate cancer risk did not vary by aspirin use. Our findings do not support a role for T. vaginalis in the etiology of advanced prostate cancer. Full article
(This article belongs to the Special Issue Urologic Oncology in Focus: Insights, Trends, Evidence-Based Practices and Future Directions)
13 pages, 1236 KiB  
Article
Towards the Definition of Radiomic Features and Clinical Indices to Enhance the Diagnosis of Clinically Significant Cancers in PI-RADS 4 and 5 Lesions
by Pietro Andrea Bonaffini, Elisabetta De Bernardi, Andrea Corsi, Paolo Niccolò Franco, Dario Nicoletta, Riccardo Muglia, Giovanna Perugini, Marco Roscigno, Mariaelena Occhipinti, Luigi Filippo Da Pozzo and Sandro Sironi
Cancers 2023, 15(20), 4963; https://doi.org/10.3390/cancers15204963 - 12 Oct 2023
Viewed by 967
Abstract
Prostate cancer (PC) is the most frequently diagnosed cancer among adult men, and its incidence is increasing worldwide [...] Full article
(This article belongs to the Special Issue Urologic Oncology in Focus: Insights, Trends, Evidence-Based Practices and Future Directions)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

19 pages, 406 KiB  
Review
CEUS Bosniak Classification—Time for Differentiation and Change in Renal Cyst Surveillance
by Kathleen Möller, Christian Jenssen, Jean Michel Correas, Ehsan Safai Zadeh, Michele Bertolotto, André Ignee, Yi Dong, Vito Cantisani and Christoph F. Dietrich
Cancers 2023, 15(19), 4709; https://doi.org/10.3390/cancers15194709 - 25 Sep 2023
Cited by 2 | Viewed by 1892
Abstract
It is time for a change. CEUS is an established method that should be much more actively included in renal cyst monitoring strategies. This review compares the accuracies, strengths, and weaknesses of CEUS, CECT, and MRI in the classification of renal cysts. In [...] Read more.
It is time for a change. CEUS is an established method that should be much more actively included in renal cyst monitoring strategies. This review compares the accuracies, strengths, and weaknesses of CEUS, CECT, and MRI in the classification of renal cysts. In order to avoid overstaging by CEUS, a further differentiation of classes IIF, III, and IV is required. A further development in the refinement of the CEUS-Bosniak classification aims to integrate CEUS more closely into the monitoring of renal cysts and to develop new and complex monitoring algorithms. Full article
(This article belongs to the Special Issue Urologic Oncology in Focus: Insights, Trends, Evidence-Based Practices and Future Directions)

Other

Jump to: Research, Review

11 pages, 5853 KiB  
Systematic Review
Predictive Value of the Mayo Adhesive Probability (MAP) Score in Laparoscopic Partial Nephrectomies: A Systematic Review from the EAU Section of Uro-Technology (ESUT)
by Panagiotis Kallidonis, Theodoros Spinos, Patricia Zondervan, Peter Nyirády, Miguel Ramírez Backhaus, Salvatore Micali, Stephan Hruby, Mario Alvarez-Maestro, Vasileios Tatanis, Evangelos Liatsikos and Ali Serdar Gözen
Cancers 2024, 16(8), 1455; https://doi.org/10.3390/cancers16081455 - 10 Apr 2024
Viewed by 465
Abstract
The Mayo Adhesive Probability (MAP) score is a radiographic scoring system that predicts the presence of adherent perinephric fat (APF) during partial nephrectomies (PNs). The purpose of this systematic review is to summarize the current literature on the application of the MAP score [...] Read more.
The Mayo Adhesive Probability (MAP) score is a radiographic scoring system that predicts the presence of adherent perinephric fat (APF) during partial nephrectomies (PNs). The purpose of this systematic review is to summarize the current literature on the application of the MAP score for predicting intraoperative difficulties related to APF and complications in laparoscopic PNs. Three databases, PubMed, Scopus and Cochrane, were screened, from inception to 29 October 2023, taking into consideration the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines. All the inclusion criteria were met by eight studies. The total operative time was around two hours in most studies, while the warm ischemia time was <30 min in all studies and <20 min in four studies. Positive surgical margins, conversion and transfusion rates ranged from 0% to 6.3%, from 0% to 5.0% and from 0.7% to 7.5%, respectively. Finally, the majority of the complications were classified as Grade I-II, according to the Clavien–Dindo Classification System. The MAP score is a useful tool for predicting not only the presence of APF during laparoscopic PNs but also various intraoperative and postoperative characteristics. It was found to be significantly associated with an increased operative time, estimated blood loss and intraoperative and postoperative complication rates. Full article
(This article belongs to the Special Issue Urologic Oncology in Focus: Insights, Trends, Evidence-Based Practices and Future Directions)
►▼ Show Figures

Figure 1

15 pages, 2583 KiB  
Systematic Review
Near-Infrared Fluorescence Imaging with Indocyanine Green for Robot-Assisted Partial Nephrectomy: A Systematic Review and Meta-Analysis
by Carlo Giulioni, Prashant Motiram Mulawkar, Daniele Castellani, Virgilio De Stefano, Carlotta Nedbal, Nariman Gadzhiev, Giacomo Maria Pirola, Yu Xi Terence Law, Marcelo Langer Wroclawski, William Ong Lay Keat, Ho Yee Tiong, Bhaskar Kumar Somani, Andrea Benedetto Galosi and Vineet Gauhar
Cancers 2023, 15(23), 5560; https://doi.org/10.3390/cancers15235560 - 24 Nov 2023
Viewed by 895
Abstract
Background: We aimed to analyze the influence of near-infrared fluorescence (NIRF) using indocyanine green (ICG) with standard robot-assisted partial nephrectomy (RAPN) in patients with a kidney tumor (KT). Methods: We performed a literature search on 12 September 2023 through PubMed, EMBASE, and Scopus. [...] Read more.
Background: We aimed to analyze the influence of near-infrared fluorescence (NIRF) using indocyanine green (ICG) with standard robot-assisted partial nephrectomy (RAPN) in patients with a kidney tumor (KT). Methods: We performed a literature search on 12 September 2023 through PubMed, EMBASE, and Scopus. The analysis included observational studies that examined the perioperative and long-term outcomes of patients with a KT who underwent RAPN with NIRF. Results: Overall, eight prospective studies, involving 535 patients, were eligible for this meta-analysis, with 212 participants in the ICG group and 323 in the No ICG group. For warm ischemia time, the ICG group showed a lower duration (weighted Mean difference (WMD) = −2.05, 95% confidence interval (CI) = −3.30–−0.80, p = 0.011). The postoperative eGFR also favored the ICG group (WMD = 7.67, 95% CI = 2.88–12.46, p = 0.002). No difference emerged for the other perioperative outcomes between the two groups. In terms of oncological radicality, the positive surgical margins and tumor recurrence rates were similar among the two groups. Conclusions: Our meta-analysis showed that NIRF with ICG during RAPN yields a favorable impact on functional outcomes, whereas it exerts no such influence on oncological aspects. Therefore, NIRF should be adopted when preserving nephron function is a paramount concern. Full article
(This article belongs to the Special Issue Urologic Oncology in Focus: Insights, Trends, Evidence-Based Practices and Future Directions)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop